Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Machine learning for health data science, fuelled by proliferation of data and reduced computational costs, has garnered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results